CYP2D6-inhibiting drugs and risk of fall injury after newly initiated therapy with beta-blockers—a register-based case-crossover study
Abstract We assessed whether concomitant use of CYP2D6-inhibiting drugs associates with increased risk of fall injuries after newly initiated therapy with beta-blockers. A case-crossover study design was applied which eliminates confounding from individual fixed characteristics by pairing cases with...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-09617-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849235454515216384 |
|---|---|
| author | Karin Leander M.-L. Dahl M. Vikström J. Möller K. Söderberg-Löfdal |
| author_facet | Karin Leander M.-L. Dahl M. Vikström J. Möller K. Söderberg-Löfdal |
| author_sort | Karin Leander |
| collection | DOAJ |
| description | Abstract We assessed whether concomitant use of CYP2D6-inhibiting drugs associates with increased risk of fall injuries after newly initiated therapy with beta-blockers. A case-crossover study design was applied which eliminates confounding from individual fixed characteristics by pairing cases with themselves across time. Data on prescribed and dispensed beta-blockers and hospitalizations for first-time fall injuries in the Swedish population aged ≥ 20 for the period 2006-01-01–2013-12-31 were extracted from national registers. Odds ratios (OR) with 95% confidence interval (CI) of fall injury associated with newly initiated beta-blocker therapy (prescription dispensed within the 28 days preceding the fall injury) while considering concomitant use of CYP2D6-inhibiting drugs, were estimated. Newly initiated beta-blocker therapy (any type) with concomitant use of CYP2D6-inhibiting drugs (any type) was associated with an increased risk of fall injury (OR 1.37, 1.24–1.52). This risk became elevated after restriction to concomitant use of moderate (OR 1.63, 1.26–2.10) or strong CYP2D6 inhibitors (OR 2.25, 1.39–3.63). The results remained similar independent of the beta-blockers’ degree of CYP2D6 metabolism (none, partial or major). Our study indicates the presence of drug-drug interaction for concomitant use of beta-blockers and CYP2D6 inhibitors in relation to the risk of fall injury, irrespective of degree of CYP2D6 metabolism. |
| format | Article |
| id | doaj-art-5331bfd9aa7d4641b084dacc593ef871 |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-5331bfd9aa7d4641b084dacc593ef8712025-08-20T04:02:46ZengNature PortfolioScientific Reports2045-23222025-07-011511810.1038/s41598-025-09617-4CYP2D6-inhibiting drugs and risk of fall injury after newly initiated therapy with beta-blockers—a register-based case-crossover studyKarin Leander0M.-L. Dahl1M. Vikström2J. Möller3K. Söderberg-Löfdal4Institute of Environmental Medicine, Unit of Cardiovascular and Nutritional Epidemiology, Karolinska InstitutetDivision of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University HospitalInstitute of Environmental Medicine, Unit of Cardiovascular and Nutritional Epidemiology, Karolinska InstitutetDepartment of Global Public Health, Karolinska InstitutetDivision of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University HospitalAbstract We assessed whether concomitant use of CYP2D6-inhibiting drugs associates with increased risk of fall injuries after newly initiated therapy with beta-blockers. A case-crossover study design was applied which eliminates confounding from individual fixed characteristics by pairing cases with themselves across time. Data on prescribed and dispensed beta-blockers and hospitalizations for first-time fall injuries in the Swedish population aged ≥ 20 for the period 2006-01-01–2013-12-31 were extracted from national registers. Odds ratios (OR) with 95% confidence interval (CI) of fall injury associated with newly initiated beta-blocker therapy (prescription dispensed within the 28 days preceding the fall injury) while considering concomitant use of CYP2D6-inhibiting drugs, were estimated. Newly initiated beta-blocker therapy (any type) with concomitant use of CYP2D6-inhibiting drugs (any type) was associated with an increased risk of fall injury (OR 1.37, 1.24–1.52). This risk became elevated after restriction to concomitant use of moderate (OR 1.63, 1.26–2.10) or strong CYP2D6 inhibitors (OR 2.25, 1.39–3.63). The results remained similar independent of the beta-blockers’ degree of CYP2D6 metabolism (none, partial or major). Our study indicates the presence of drug-drug interaction for concomitant use of beta-blockers and CYP2D6 inhibitors in relation to the risk of fall injury, irrespective of degree of CYP2D6 metabolism.https://doi.org/10.1038/s41598-025-09617-4Accidental fallsBeta-blocking agentsCytochrome P450 CYP2D6 inhibitorsDrug interactions |
| spellingShingle | Karin Leander M.-L. Dahl M. Vikström J. Möller K. Söderberg-Löfdal CYP2D6-inhibiting drugs and risk of fall injury after newly initiated therapy with beta-blockers—a register-based case-crossover study Scientific Reports Accidental falls Beta-blocking agents Cytochrome P450 CYP2D6 inhibitors Drug interactions |
| title | CYP2D6-inhibiting drugs and risk of fall injury after newly initiated therapy with beta-blockers—a register-based case-crossover study |
| title_full | CYP2D6-inhibiting drugs and risk of fall injury after newly initiated therapy with beta-blockers—a register-based case-crossover study |
| title_fullStr | CYP2D6-inhibiting drugs and risk of fall injury after newly initiated therapy with beta-blockers—a register-based case-crossover study |
| title_full_unstemmed | CYP2D6-inhibiting drugs and risk of fall injury after newly initiated therapy with beta-blockers—a register-based case-crossover study |
| title_short | CYP2D6-inhibiting drugs and risk of fall injury after newly initiated therapy with beta-blockers—a register-based case-crossover study |
| title_sort | cyp2d6 inhibiting drugs and risk of fall injury after newly initiated therapy with beta blockers a register based case crossover study |
| topic | Accidental falls Beta-blocking agents Cytochrome P450 CYP2D6 inhibitors Drug interactions |
| url | https://doi.org/10.1038/s41598-025-09617-4 |
| work_keys_str_mv | AT karinleander cyp2d6inhibitingdrugsandriskoffallinjuryafternewlyinitiatedtherapywithbetablockersaregisterbasedcasecrossoverstudy AT mldahl cyp2d6inhibitingdrugsandriskoffallinjuryafternewlyinitiatedtherapywithbetablockersaregisterbasedcasecrossoverstudy AT mvikstrom cyp2d6inhibitingdrugsandriskoffallinjuryafternewlyinitiatedtherapywithbetablockersaregisterbasedcasecrossoverstudy AT jmoller cyp2d6inhibitingdrugsandriskoffallinjuryafternewlyinitiatedtherapywithbetablockersaregisterbasedcasecrossoverstudy AT ksoderberglofdal cyp2d6inhibitingdrugsandriskoffallinjuryafternewlyinitiatedtherapywithbetablockersaregisterbasedcasecrossoverstudy |